5549. Lobaplatin

Nomenclature

CAS number: 135558-11-1
(SP-4-3)-[rel-(1R,2R)-1,2-Cyclobutanedimethanamine-κN,κN′][(2S)-2-(hydroxy-κO)propanoato(2)-κO]platinum; cis-[trans-1,2-cyclobutanebis(methylamine)][(S)-lactato-O1,O2]platinum; D-19466.
C9H18N2O3Pt; mol wt 397.33.
C 27.21%, H 4.57%, N 7.05%, O 12.08%, Pt 49.10%.

Description and references

Water-soluble platinum compound; mixture of two trans diastereoisomers. Prepn: W. Schumacher et al., EP 324154; eidem, US 5023335 (1989, 1991 both to ASTA Pharma); and pharmacology: R. Voegeli et al., J. Cancer Res. Clin. Oncol. 116, 439 (1990). HPLC determn of diastereoisomers in plasma: J. Welink et al., J. Chromatogr. B 675, 107 (1996). Clinical evaluation: M. Degardin et al., Invest. New Drugs 13, 253 (1995); and pharmacokinetics: J. A. Gietema et al., Br. J. Cancer 71, 1302 (1995). Evaluation in canine osteosarcoma: J. Kirpensteijn et al., Anticancer Res. 22, 2765 (2002). Review of clinical development: M. J. McKeage, Expert Opin. Invest. Drugs 10, 119-128 (2001).

Chemical structure

Properties

Crystals from diethyl ether, mp 220° (dec). Sol in water. LD50 i.p. in mice: 46 mg/kg (Voegeli).

Therapeutic Category

Antineoplastic.

Therapeutic Category (Veterinary)

Antineoplastic.

Keywords

Antineoplastic; Platinum Complexes